SAM
LKFT

Smartleaf Asset Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Smartleaf Asset Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4K Sell
360
-29
-7% -$960 ﹤0.01% 2313
2025
Q4 		$12.7K Buy
+389
New +$12.6K ﹤0.01% 2284

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Smartleaf Asset Management's LKFT Position: Q1 2026 in Review

Smartleaf Asset Management reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 7.5% in Q1 2026, selling an estimated $960 and leaving 360 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2313.

Smartleaf Asset Management first reported a position in LKFT in Q4 2025 and has held it in 2 quarters since. The position peaked at $12.7K in Q4 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Smartleaf Asset Management held 360 shares of Lakefront Biotherapeutics American Depositary Shares worth $10.4K as of Q1 2026.
  • Smartleaf Asset Management sold 29 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $960.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2313 holding.
  • Smartleaf Asset Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2025 and has held it in 2 quarters since.
  • Smartleaf Asset Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $12.7K in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.